Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 13/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856823 | 0.91 | MYC (0.62) | MYCLMNACYP1A2CYP2E1CYP3A4 | |
| SCHEMBL2105446 | 0.86 | MYC (0.41) | MYCSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2106535 | 0.85 | MYC (0.54) | MYCSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2107579 | 0.85 | MYC (0.43) | MYCSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2106226 | 0.84 | MYC (0.47) | MYCSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2104429 | 0.82 | ALDH1A1 (0.51) | MYCSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2105831 | 0.79 | MYC (0.52) | MYCSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2100202 | 0.79 | MYC (0.67) | MYCSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2107082 | 0.78 | ALDH1A1 (0.47) | MYCSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2105385 | 0.78 | MYC (0.58) | MYCSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163768-B2 | 4-(4-Hydroxy-3-methyl-phenyl)-2,4,6,7,8,9-hexahydro-pyrazolo[3,4-b]-1,7-naphthyridin-5-one; inhibiting Aurora kinase; inhibiting the proliferation of tumor cells; cancer, psoriasis, leukaemia and lupus | AVENTIS PHARMA S.A.. (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-1910366-B1 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1910366-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012972-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | DPYD, DHPS, QDPR | MYC 3202/4885SMN1; SMN2 976/4885MEN1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.